Imatinib mesylate in the treatment of hematologic malignancies.
about
Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KITPhase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosisMalignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signalingUnscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity.Manipulating B cell homeostasis: a key component in the advancement of targeted strategiesNovel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluationIdentification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.Precision oncology: neither a silver bullet nor a dream.Angiogenesis inhibitors in early development for gastric cancer.Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.
P2860
Q28553167-353E9E2D-D23F-4E08-8E1B-BF3D639D1C87Q34284684-3B1105D9-CA1B-436F-922A-7A595B29EDCEQ34284691-43947BC9-7894-4B81-BAF7-B83727B7B5FDQ34309316-3A4C1C82-8533-4B4B-A47E-249B3FA63BD9Q37099933-F6C920A0-A69C-47EB-BAF3-90B44F69AF61Q37177128-A062961B-06DB-42F2-B509-DACD6F86DC9EQ37248354-9F38550B-A4D2-4B0F-A8CD-F9E76A24A9EDQ38066199-33C74AD0-3D0C-492E-B8C9-464979D3024CQ39499397-3CA4CF4F-E97C-4538-9C46-7F56E998FE14Q47737073-9EB962CB-961F-4808-814E-91F2C400043BQ47996955-5190E831-6570-4D5C-8BBF-9109B5DBD5D8Q54348243-1391875D-620A-41B7-9CE5-70DFFD2001FD
P2860
Imatinib mesylate in the treatment of hematologic malignancies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Imatinib mesylate in the treatment of hematologic malignancies.
@en
type
label
Imatinib mesylate in the treatment of hematologic malignancies.
@en
prefLabel
Imatinib mesylate in the treatment of hematologic malignancies.
@en
P2860
P50
P1476
Imatinib mesylate in the treatment of hematologic malignancies.
@en
P2093
Pier Paolo Piccaluga
Stefania Paolini
P2860
P304
P356
10.1517/14712598.7.10.1597
P407
P577
2007-10-01T00:00:00Z